Department of Pediatrics, Division of Infectious Disease, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Department of Pediatrics, Division of Infectious Disease, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
J Virol. 2023 Apr 27;97(4):e0016023. doi: 10.1128/jvi.00160-23. Epub 2023 Mar 20.
Host-derived cellular pathways can provide an unfavorable environment for virus replication. These pathways have been a subject of interest for herpesviruses, including the betaherpesvirus human cytomegalovirus (HCMV). Here, we demonstrate that a compound, ARP101, induces the noncanonical sequestosome 1 (SQSTM1)/p62-Keap1-Nrf2 pathway for HCMV suppression. ARP101 increased the levels of both LC3 II and SQSTM1/p62 and induced phosphorylation of p62 at the C-terminal domain, resulting in its increased affinity for Keap1. ARP101 treatment resulted in Nrf2 stabilization and translocation into the nucleus, binding to specific promoter sites and transcription of antioxidant enzymes under the antioxidant response element (ARE), and HCMV suppression. Knockdown of Nrf2 recovered HCMV replication following ARP101 treatment, indicating the role of the Keap1-Nrf2 axis in HCMV inhibition by ARP101. SQSTM1/p62 phosphorylation was not modulated by the mTOR kinase or casein kinase 1 or 2, indicating ARP101 engages other kinases. Together, the data uncover a novel antiviral strategy for SQSTM1/p62 through the noncanonical Keap1-Nrf2 axis. This pathway could be further exploited, including the identification of the responsible kinases, to define the biological events during HCMV replication. Antiviral treatment for human cytomegalovirus (HCMV) is limited and suffers from the selection of drug-resistant viruses. Several cellular pathways have been shown to modulate HCMV replication. The autophagy receptor sequestosome 1 (SQSTM1)/p62 has been reported to interact with several HCMV proteins, particularly with components of HCMV capsid, suggesting it plays a role in viral replication. Here, we report on a new and unexpected role for SQSTM1/p62, in HCMV suppression. Using a small-molecule probe, ARP101, we show SQSTM1/p62 phosphorylation at its C terminus domain initiates the noncanonical Keap1-Nrf2 axis, leading to transcription of genes under the antioxidant response element, resulting in HCMV inhibition Our study highlights the dynamic nature of SQSTM1/p62 during HCMV infection and how its phosphorylation activates a new pathway that can be exploited for antiviral intervention.
宿主来源的细胞途径可能为病毒复制提供不利环境。这些途径一直是疱疹病毒(包括β疱疹病毒人巨细胞病毒(HCMV))的研究热点。在这里,我们证明了一种化合物 ARP101 可诱导非典型的自噬体 1(SQSTM1)/p62-Keap1-Nrf2 途径来抑制 HCMV。ARP101 增加了 LC3 II 和 SQSTM1/p62 的水平,并诱导 p62 在 C 端结构域磷酸化,从而增加其与 Keap1 的亲和力。ARP101 处理导致 Nrf2 稳定并转位入核,与抗氧化反应元件(ARE)下的特定启动子位点结合,并转录抗氧化酶,从而抑制 HCMV。ARP101 处理后,Nrf2 的敲低恢复了 HCMV 的复制,表明 Keap1-Nrf2 轴在 ARP101 抑制 HCMV 中的作用。SQSTM1/p62 的磷酸化不受 mTOR 激酶或酪蛋白激酶 1 或 2 的调节,表明 ARP101 涉及其他激酶。总之,数据揭示了一种通过非典型的 Keap1-Nrf2 轴靶向 SQSTM1/p62 的新型抗病毒策略。该途径可以进一步开发,包括确定负责的激酶,以定义 HCMV 复制过程中的生物学事件。 人巨细胞病毒(HCMV)的抗病毒治疗有限,并且受到耐药病毒选择的影响。已经证明几种细胞途径可调节 HCMV 复制。自噬受体 SQSTM1/p62 已被报道与几种 HCMV 蛋白相互作用,特别是与 HCMV 衣壳的组成部分相互作用,表明其在病毒复制中起作用。在这里,我们报告了 SQSTM1/p62 在 HCMV 抑制中的一个新的、意想不到的作用。使用小分子探针 ARP101,我们显示 SQSTM1/p62 在其 C 端结构域的磷酸化启动了非典型的 Keap1-Nrf2 轴,导致抗氧化反应元件下基因的转录,从而抑制 HCMV。 我们的研究强调了 SQSTM1/p62 在 HCMV 感染过程中的动态性质,以及其磷酸化如何激活可用于抗病毒干预的新途径。